Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=6 Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Dense Deposit Disease · Membranoproliferative Glomerulonephritis
Primary: Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period — 5 Participants
N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Early Phase 1 N=16 Calcitriol Monotherapy for X-Linked Hypophosphatemia
X-linked Hypophosphatemia · Hypophosphatemic Rickets · Hypophosphatemic Rickets, X-Linked Dominant
Primary: Change in Serum Phosphate in Adults and Children With XLH Between Baseline and 12 Months — 2.6; 2.1 mg/dl — p=0.318
N/A N=21 Calcitonin for Treating X-linked Hypophosphatemia
Hypophosphatemic Rickets, X Linked Dominant
Primary: Area Under the Curve for FGF23 — 3172.34; 3215.34 pg/ml*hr
Phase 3 N=34 Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Primary: Change in Mean Serum Copeptin From Baseline (a Reflection of Endogenous Vasopressin Production) at Week 2 — -0.86; 0.39 pmole/L — p=<0.01
Phase 3 N=74 The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
Chronic Renal Insufficiency · Proteinuria
Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine
Phase 1 N=32 Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis
Renal Impairment
Primary: Number of Participants With Clinically Significant Hypocalcemia — 1; 2 participants
N/A N=18 FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
Secondary Hyperparathyroidism
Primary: Change in FGF-23 Level — 16; 41 percentage change from baseline
N/A N=43 Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)
Kidney Disease
Primary: Percentage Changes in Fibroblast Growth Factor-23 (FGF-23) Levels — -0.35; 0.25; 0.00; -0.02 percentage of change from baseline
Phase 2 N=12 Podocyte Retinoids
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
N/A N=3 Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease
Phosphorus and Calcium Disorders · Chronic Kidney Disease Mineral and Bone Disorder · Chronic Kidney Diseases
Primary: Fractional Calcium Absorption — 0.30; 0.42 fraction of 1.00
Phase 4 N=204 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder
Vitamin D Deficiency
Primary: The Blood Levels of Calcium at the 24th Month of Following up. — 2.31; 2.33 mmol/L — p=0.117
N/A N=16 Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
Chronic Kidney Disease
Primary: Fibroblast Growth Factor 23 (FGF-23) — 162.695; 297; 188.975; 143.7675 RU/ml
Phase 2 N=12 Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
Fibrous Dysplasia Of Bone
Primary: Proportion of Participants With Serum Phosphate Levels Within the Target Range at Week 48 — 1 Proportion of participant
N/A N=56 Impact of Vitamin D Therapies on Chronic Kidney Disease
Chronic Kidney Disease (CKD) · End-stage Renal Disease (ESRD)
Primary: Monocyte Protein Expression — 34110; 38540; 1359; 1360 relative fluorescence units
Phase 2 N=7 Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)
Arterial Calcification · CD73 Deficiency
Primary: Ankle-brachial Index at Rest at Pre-treatment, On-treatment and Post-treatment of Etidronate in Participants Diagnosed With ACDC — 0.5741; 0.5411; 0.5222; 0.5266 score…
N/A N=51 Kidney and Periodontal Disease Study
Chronic Kidney Disease · Periodontal Disease
Primary: Number of Participants Completing Study Protocol — 17; 34; 14; 30 Participants
Phase 2 N=31 The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
Primary: Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients — 656.8; 190.9; 681.3; 156.9 ng/mL
Phase 4 N=309 20070360 Incident Dialysis
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
Phase 4 N=43 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis
Osteoporosis, Postmenopausal · Periodontitis
Primary: Sost Values for 6th Month — 1389.177; 1085.405; 1596.585; 2131.87 ng/ml — p=<0.01
N/A N=54 Impact of Vitamin D on Diabetic Kidney Disease in African Americans
Diabetic Kidney Disease
Primary: Change in Urinary Albumin:Creatinine Ratio (ACR) — -52.55555556; 46.44444444 ratio
Phase 4 N=41 A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease
Chronic Kidney Disease, Stage 5 · Secondary Hyperparathyroidism
Primary: Calcium Absorption Fractions Analyzed by Analysis of Variance (ANOVA) — 0.103; 0.108 Fractions — p=0.573
Phase 3 N=33 Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
Hypophosphatemia, Familial · Hyperparathyroidism
Primary: Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement — 1223; 1449; 987; 1616 nlEq*26hr/ml — p=0.007
Phase 3 N=13 A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
End-Stage Renal Disease · Secondary Hyperparathyroidism
Primary: Percentage of Subjects With Hypercalcemia — 15.3 percentage of participants
N/A N=6 Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease
Chronic Kidney Disease · Bacterial Infection
Primary: Maximum Plasma Concentration (Cmax) — 42.4; 66.5 mg/L
Phase 3 N=8 Steroid Treatment for Kidney Disease
Nephrosis · Focal Lipoid Glomerulosclerosis
Primary: Remission Status of Patients After Intermittent Oral Dexamethasone Administered Over 48 Weeks — 1; 1; 2; 1 participants — p=0.9074
Phase 4 N=28 Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g
Phase 2 N=60 Study of LY3016859 in Participants With Diabetic Nephropathy
Diabetic Nephropathy
Primary: Part B:Change From Baseline in Proteinuria — 1.5; -0.4; 0.1; 0.7 grams per 12 hour (g/12 hour) — p=0.0449
Phase 2 N=599 A Phase 2b Diabetic Kidney Disease Study
Diabetic Kidney Disease
Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population — -14.82; -17.25; -31.45; -29.70 Percentage change from baseline — p=0.8338